68 research outputs found
Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
ROR1 (receptor tyrosine kinase-like orphan receptor 1) is a conserved, oncoembryonic surface antigen expressed in chronic lymphocytic leukemia (CLL). We found that ROR1 associates with hematopoietic-lineage-cell-specific protein 1 (HS1) in freshly isolated CLL cells or in CLL cells cultured with exogenous Wnt5a. Wnt5a also induced HS1 tyrosine phosphorylation, recruitment of ARHGEF1, activation of RhoA and enhanced chemokine-directed migration; such effects could be inhibited by cirmtuzumab, a humanized anti-ROR1 mAb. We generated truncated forms of ROR1 and found its extracellular cysteine-rich domain or kringle domain was necessary for Wnt5a-induced HS1 phosphorylation. Moreover, the cytoplamic, and more specifically the proline-rich domain (PRD), of ROR1 was required for it to associate with HS1 and allow for F-actin polymerization in response to Wnt5a. Accordingly, we introduced single amino acid substitutions of proline (P) to alanine (A) in the ROR1 PRD at positions 784, 808, 826, 841 or 850 in potential SH3-binding motifs. In contrast to wild-type ROR1, or other ROR1PâïžA mutants, ROR1P(841)A had impaired capacity to recruit HS1 and ARHGEF1 to ROR1 in response to Wnt5a. Moreover, Wnt5a could not induce cells expressing ROR1P(841)A to phosphorylate HS1 or activate ARHGEF1, and was unable to enhance CLL-cell motility. Collectively, these studies indicate HS1 plays an important role in ROR1-dependent Wnt5a-enhanced chemokine-directed leukemia-cell migration
A polygenic risk score for multiple myeloma risk prediction
There is overwhelming epidemiologic evidence that the risk of multiple myeloma (MM) has a solid genetic background. Genome-wide association studies (GWAS) have identified 23 risk loci that contribute to the genetic susceptibility of MM, but have low individual penetrance. Combining the SNPs in a polygenic risk score (PRS) is a possible approach to improve their usefulness. Using 2361 MM cases and 1415 controls from the International Multiple Myeloma rESEarch (IMMEnSE) consortium, we computed a weighted and an unweighted PRS. We observed associations with MM risk with OR = 3.44, 95% CI 2.53â4.69, p = 3.55 Ă 10â15 for the highest vs. lowest quintile of the weighted score, and OR = 3.18, 95% CI 2.1 = 34â4.33, p = 1.62 Ă 10â13 for the highest vs. lowest quintile of the unweighted score. We found a convincing association of a PRS generated with 23 SNPs and risk of MM. Our work provides additional validation of previously discovered MM risk variants and of their combination into a PRS, which is a first step towards the use of genetics for risk stratification in the general population
Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
Canadian Institutes of Health Research, Grant/
Award Number: 81274; Huntsman Cancer
Institute Pilot Funds; Leukemia Lymphoma
Society, Grant/Award Number: 6067-09; the
National Institute of Health/National Cancer
Institute, Grant/Award Numbers: P30
CA016672, P30 CA042014, P30 CA13148,
P50 CA186781, R01 CA107476, R01
CA134674, R01 CA168762, R01 CA186646,
R01 CA235026, R21 CA155951, R25 CA092049, R25 CA47888, U54 CA118948;
Utah Population Database, Utah Cancer
Registry, Huntsman Cancer Center Support
Grant, Utah State Department of Health,
University of Utah; VicHealth, Cancer Council
Victoria, Australian National Health and
Medical Research Council, Grant/Award
Numbers: 1074383, 209057, 396414;
Victorian Cancer Registry, Australian Institute
of Health and Welfare, Australian National
Death Index, Australian Cancer Database;
Mayo Clinic Cancer Center; University of Pisa
and DKFZThe authors thank all site investigators that contributed to the studies
within the Multiple Myeloma Working Group (Interlymph Consortium),
staff involved at each site and, most importantly, the study participants
for their contributions that made our study possible. This work was partially
supported by intramural funds of University of Pisa and DKFZ. This
work was supported in part by the National Institute of Health/National
Cancer Institute (R25 CA092049, P30 CA016672, R01 CA134674, P30
CA042014, R01 CA186646, R21 CA155951, U54 CA118948, P30
CA13148, R25 CA47888, R01 CA235026, R01 CA107476, R01
CA168762, P50 CA186781 and the NCI Intramural Research Program),
Leukemia Lymphoma Society (6067-09), Huntsman Cancer Institute
Pilot Funds, Utah PopulationDatabase, Utah Cancer Registry, Huntsman
Cancer Center Support Grant, Utah StateDepartment of Health, University
of Utah, Canadian Institutes of Health Research (Grant number
81274), VicHealth, Cancer Council Victoria, Australian National Health
and Medical Research Council (Grants 209057, 396414, 1074383), Victorian
Cancer Registry, Australian Institute of Health and Welfare,
Australian National Death Index, Australian Cancer Database and the
Mayo Clinic Cancer Center.Open Access funding enabled and organized
by ProjektDEAL.The data that support the findings of this study are available on
request from the corresponding author. The data are not publicly
available due to privacy or ethical restrictions.Gene expression profiling can be used for predicting survival in multiple myeloma (MM) and identifying patients who will benefit from particular types of therapy. Some germline single nucleotide polymorphisms (SNPs) act as expression quantitative trait loci (eQTLs) showing strong associations with gene expression levels. We performed an association study to test whether eQTLs of genes reported to be associated with prognosis of MM patients are directly associated with measures of adverse outcome. Using the genotype-tissue expression portal, we identified a total of 16 candidate genes with at least one eQTL SNP associated with their expression with P < 10(-7) either in EBV-transformed B-lymphocytes or whole blood. We genotyped the resulting 22 SNPs in 1327 MM cases from the International Multiple Myeloma rESEarch (IMMEnSE) consortium and examined their association with overall survival (OS) and progression-free survival (PFS), adjusting for age, sex, country of origin and disease stage. Three polymorphisms in two genes (TBRG4-rs1992292, TBRG4-rs2287535 and ENTPD1-rs2153913) showed associations with OS at P < .05, with the former two also associated with PFS. The associations of two polymorphisms in TBRG4 with OS were replicated in 1277 MM cases from the International Lymphoma Epidemiology (InterLymph) Consortium. A meta-analysis of the data from IMMEnSE and InterLymph (2579 cases) showed that TBRG4-rs1992292 is associated with OS (hazard ratio = 1.14, 95% confidence interval 1.04-1.26, P = .007). In conclusion, we found biologically a plausible association between a SNP in TBRG4 and OS of MM patients.Canadian Institutes of Health Research (CIHR)
81274Huntsman Cancer Institute Pilot FundsLeukemia and Lymphoma Society
6067-09United States Department of Health & Human Services
National Institutes of Health (NIH) - USA
NIH National Cancer Institute (NCI)
P30 CA016672
P30 CA042014
P30 CA13148
P50 CA186781
R01 CA107476
R01 CA134674
R01 CA168762
R01 CA186646
R01 CA235026
R21 CA155951
R25 CA092049
R25 CA47888
U54 CA118948Utah Population Database, Utah Cancer Registry, Huntsman Cancer Center Support Grant, Utah State Department of Health, University of UtahVicHealth, Cancer Council Victoria, Australian National Health and Medical Research Council
1074383
209057
396414Victorian Cancer Registry, Australian Institute of Health and Welfare, Australian National Death Index, Australian Cancer DatabaseMayo Clinic Cancer CenterUniversity of PisaHelmholtz Associatio
Identification of miRSNPs associated with the risk of multiple myeloma
Accepted articleMultiple myeloma (MM) is a malignancy of plasma cells usually infiltrating the bone marrow, associated with the production of a monoclonal immunoglobulin (M protein) which can be detected in the blood and/or urine. Multiple lines of evidence suggest that genetic factors are involved in MM pathogenesis, and several studies have identified single nucleotide polymorphisms (SNPs) associated with the susceptibility to the disease. SNPs within miRNA-binding sites in target genes (miRSNPs) may alter the strength of miRNA-mRNA interactions, thus deregulating protein expression. MiRSNPs are known to be associated with risk of various types of cancer, but they have never been investigated in MM. We performed an in silico genome-wide search for miRSNPs predicted to alter binding of miRNAs to their target sequences. We selected 12 miRSNPs and tested their association with MM risk. Our study population consisted of 1,832 controls and 2,894 MM cases recruited from seven European countries and Israel in the context of the IMMEnSE (International Multiple Myeloma rESEarch) consortium. In this population two SNPs showed an association with p<0.05: rs286595 (located in gene MRLP22) and rs14191881 (located in gene TCF19). Results from IMMEnSE were meta-analyzed with data from a previously published genome-wide association study (GWAS). The SNPs rs13409 (located in the 3UTR of the POU5F1 gene), rs1419881 (TCF19), rs1049633, rs1049623 (both in DDR1) showed significant associations with MM risk. In conclusion, we sought to identify genetic polymorphisms associated with MM risk starting from genome-wide prediction of miRSNPs. For some mirSNPs, we have shown promising associations with MM risk.
What's new? Even though deregulation of miRNA expression has been associated with human cancers little information is available regarding their relation with MM susceptibility. We performed an in silico genome-wide search for miRSNPs and selected the most promising ones for an association study. The SNPs with the strongest associations with MM risk are localized in genes which have never been related with MM.This work was partially funded by: intramural funds of German Cancer
Research Center (DKFZ), Grant ref. HUS412A1271 from
the âGerencia Regional de Salud de la Junta de Castilla y LĂ©onâ. This work was supported by grants from the Instituto de Salud Carlos III
(Madrid, Spain; PI12/02688). Catalan Government DURSI grant 2014SGR647 and Instituto de Salud Carlos III, co7funded by FEDER funds âa way to build Europeâ grants PI11701439 and PIE13/00022info:eu-repo/semantics/publishedVersio
Polymorphisms within autophagy-related genes as susceptibility biomarkers for multiple myeloma: a meta-analysis of three large cohorts and functional characterization
Functional data used in this project have been meticulously catalogued and archived in the BBMRI-NL data infrastructure (https://hfgp.bbmri.nl/, accessed on 12 February 2020) using the MOLGENIS open-source platform for scientific data.Multiple myeloma (MM) arises following malignant proliferation of plasma cells in the
bone marrow, that secrete high amounts of specific monoclonal immunoglobulins or light chains,
resulting in the massive production of unfolded or misfolded proteins. Autophagy can have a
dual role in tumorigenesis, by eliminating these abnormal proteins to avoid cancer development,
but also ensuring MM cell survival and promoting resistance to treatments. To date no studies
have determined the impact of genetic variation in autophagy-related genes on MM risk. We
performed meta-analysis of germline genetic data on 234 autophagy-related genes from three independent study populations including 13,387 subjects of European ancestry (6863 MM patients and
6524 controls) and examined correlations of statistically significant single nucleotide polymorphisms
(SNPs; p < 1 Ă 10â9) with immune responses in whole blood, peripheral blood mononuclear
cells (PBMCs), and monocyte-derived macrophages (MDM) from a large population of healthy
donors from the Human Functional Genomic Project (HFGP). We identified SNPs in six loci, CD46,
IKBKE, PARK2, ULK4, ATG5, and CDKN2A associated with MM risk (p = 4.47 Ă 10â4â5.79 Ă 10â14).
Mechanistically, we found that the ULK4rs6599175 SNP correlated with circulating concentrations
of vitamin D3 (p = 4.0 Ă 10â4), whereas the IKBKErs17433804 SNP correlated with the number of
transitional CD24+CD38+ B cells (p = 4.8 Ă 10â4) and circulating serum concentrations of Monocyte
hemoattractant Protein (MCP)-2 (p = 3.6 Ă 10â4). We also found that the CD46rs1142469 SNP corre lated with numbers of CD19+ B cells, CD19+CD3â B cells, CD5+ IgDâ cells, IgMâ cells, IgDâIgMâ
cells, and CD4âCD8â PBMCs (p = 4.9 Ă 10â4â8.6 Ă 10â4
) and circulating concentrations of interleukin (IL)-20 (p = 0.00082). Finally, we observed that the CDKN2Ars2811710 SNP correlated with levels
of CD4+EMCD45RO+CD27â cells (p = 9.3 Ă 10â4
). These results suggest that genetic variants within
these six loci influence MM risk through the modulation of specific subsets of immune cells, as well
as vitamin D3â, MCP-2â, and IL20-dependent pathways.This work was supported by the European Unionâs Horizon 2020 research and innovation program, N° 856620 and by grants from the Instituto de Salud Carlos III and FEDER (Madrid, Spain; PI17/02256 and PI20/01845), ConsejerĂa de TransformaciĂłn EconĂłmica, Industria, Conocimiento y Universidades and FEDER (PY20/01282), from the CRIS foundation against cancer, from the Cancer Network of Excellence (RD12/10 Red de CĂĄncer), from the Dietmar Hopp Foundation and the German Ministry of Education and Science (BMBF: CLIOMMICS [01ZX1309]), and from National Cancer Institute of the National Institutes of Health under award numbers: R01CA186646, U01CA249955 (EEB).This work was also funded d by Portuguese National funds, through the Foundation for Science and Technology (FCT)âproject UIDB/50026/2020 and UIDP/50026/2020 and by the project NORTE-01-0145-FEDER-000055, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF)
Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
SARS-CoV-2-specific memory T cells will likely prove critical for long-term immune protection against COVID-19. Here, we systematically mapped the functional and phenotypic landscape of SARS-CoV-2-specific T cell responses in unexposed individuals, exposed family members, and individuals with acute or convalescent COVID-19. Acute-phase SARS-CoV-2-specific T cells displayed a highly activated cytotoxic phenotype that correlated with various clinical markers of disease severity, whereas convalescent-phase SARS-CoV-2-specific T cells were polyfunctional and displayed a stem-like memory phenotype. Importantly, SARS-CoV-2-specific T cells were detectable in antibody-seronegative exposed family members and convalescent individuals with a history of asymptomatic and mild COVID-19. Our collective dataset shows that SARS-CoV-2 elicits broadly directed and functionally replete memory T cell responses, suggesting that natural exposure or infection may prevent recurrent episodes of severe COVID-19
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
[Excerpt] Multiple myeloma (MM) is the third most common hematological malignancy, after Non-Hodgkin Lymphoma and Leukemia. MM is generally preceded by Monoclonal Gammopathy of Undetermined Significance (MGUS) [1], and epidemiological studies have identified older age, male gender, family history, and MGUS as risk factors for developing MM [2].
The somatic mutational landscape of sporadic MM has been increasingly investigated, aiming to identify recurrent genetic events involved in myelomagenesis. Whole exome and whole genome sequencing studies have shown that MM is a genetically heterogeneous disease that evolves through accumulation of both clonal and subclonal driver mutations [3] and identified recurrently somatically mutated genes, including KRAS, NRAS, FAM46C, TP53, DIS3, BRAF, TRAF3, CYLD, RB1 and PRDM1 [3,4,5].
Despite the fact that family-based studies have provided data consistent with an inherited genetic susceptibility to MM compatible with Mendelian transmission [6], the molecular basis of inherited MM predisposition is only partly understood. Genome-Wide Association (GWAS) studies have identified and validated 23 loci significantly associated with an increased risk of developing MM that explain ~16% of heritability [7] and only a subset of familial cases are thought to have a polygenic background [8]. Recent studies have identified rare germline variants predisposing to MM in KDM1A [9], ARID1A and USP45 [10], and the implementation of next-generation sequencing technology will allow the characterization of more such rare variants. [...]French National Cancer Institute (INCA) and the Fondation Française pour la Recherche contre le Myélome et les Gammapathies (FFMRG), the Intergroupe Francophone du Myélome (IFM), NCI R01 NCI CA167824 and a generous donation from Matthew Bell. This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health under award number S10OD018522. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors thank the Association des Malades du Myélome Multiple (AF3M) for their continued support and participation. Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organizatio
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization
Multiple myeloma (MM) arises following malignant proliferation of plasma cells in the bone marrow, that secrete high amounts of specific monoclonal immunoglobulins or light chains, resulting in the massive production of unfolded or misfolded proteins. Autophagy can have a dual role in tumorigenesis, by eliminating these abnormal proteins to avoid cancer development, but also ensuring MM cell survival and promoting resistance to treatments. To date no studies have determined the impact of genetic variation in autophagy-related genes on MM risk. We performed meta-analysis of germline genetic data on 234 autophagy-related genes from three independent study populations including 13,387 subjects of European ancestry (6863 MM patients and 6524 controls) and examined correlations of statistically significant single nucleotide polymorphisms (SNPs; p < 1 Ă 10â9) with immune responses in whole blood, peripheral blood mononuclear cells (PBMCs), and monocyte-derived macrophages (MDM) from a large population of healthy donors from the Human Functional Genomic Project (HFGP). We identified SNPs in six loci, CD46, IKBKE, PARK2, ULK4, ATG5, and CDKN2A associated with MM risk (p = 4.47 Ă 10â4â5.79 Ă 10â14). Mechanistically, we found that the ULK4rs6599175 SNP correlated with circulating concentrations of vitamin D3 (p = 4.0 Ă 10â4), whereas the IKBKErs17433804 SNP correlated with the number of transitional CD24+CD38+ B cells (p = 4.8 Ă 10â4) and circulating serum concentrations of Monocyte Chemoattractant Protein (MCP)-2 (p = 3.6 Ă 10â4). We also found that the CD46rs1142469 SNP correlated with numbers of CD19+ B cells, CD19+CD3â B cells, CD5+IgDâ cells, IgMâ cells, IgDâIgMâ cells, and CD4âCD8â PBMCs (p = 4.9 Ă 10â4â8.6 Ă 10â4) and circulating concentrations of interleukin (IL)-20 (p = 0.00082). Finally, we observed that the CDKN2Ars2811710 SNP correlated with levels of CD4+EMCD45RO+CD27â cells (p = 9.3 Ă 10â4). These results suggest that genetic variants within these six loci influence MM risk through the modulation of specific subsets of immune cells, as well as vitamin D3â, MCP-2â, and IL20-dependent pathways.This work was supported by the European Unionâs Horizon 2020 research and innovation program, N° 856620 and by grants from the Instituto de Salud Carlos III and FEDER (Madrid, Spain; PI17/02256 and PI20/01845), ConsejerĂa de TransformaciĂłn EconĂłmica, Industria, Conocimiento y Universidades and FEDER (PY20/01282), from the CRIS foundation against cancer, from the Cancer Network of Excellence (RD12/10 Red de CĂĄncer), from the Dietmar Hopp Foundation and the German Ministry of Education and Science (BMBF: CLIOMMICS [01ZX1309]), and from National Cancer Institute of the National Institutes of Health under award numbers: R01CA186646, U01CA249955 (EEB). This work was also funded d by Portuguese National funds, through the Foundation for Science and Technology (FCT)âproject UIDB/50026/2020 and UIDP/50026/2020 and by the project NORTE-01-0145-FEDER-000055, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF).Peer reviewe
- âŠ